The emerging role of heart-on-a-chip systems in delineating mechanisms of SARS-CoV-2-induced cardiac dysfunction.
Rick Xing Ze LuMilica RadisicMilica RadisicPublished in: Bioengineering & translational medicine (2023)
Coronavirus disease 2019 (COVID-19) has been a major global health concern since its emergence in 2019, with over 680 million confirmed cases as of April 2023. While COVID-19 has been strongly associated with the development of cardiovascular complications, the specific mechanisms by which viral infection induces myocardial dysfunction remain largely controversial as studies have shown that the severe acute respiratory syndrome coronavirus-2 can lead to heart failure both directly, by causing damage to the heart cells, and indirectly, by triggering an inflammatory response throughout the body. In this review, we summarize the current understanding of potential mechanisms that drive heart failure based on in vitro studies. We also discuss the significance of three-dimensional heart-on-a-chip technology in the context of the current and future pandemics.
Keyphrases
- respiratory syndrome coronavirus
- heart failure
- coronavirus disease
- sars cov
- left ventricular
- global health
- inflammatory response
- oxidative stress
- atrial fibrillation
- induced apoptosis
- high throughput
- cardiac resynchronization therapy
- acute heart failure
- circulating tumor cells
- public health
- diabetic rats
- risk factors
- case control
- risk assessment
- high glucose
- current status
- lipopolysaccharide induced
- immune response
- climate change
- endothelial cells
- cell death
- single cell